Scientific tool company Zymo Research reported on Thursday the receipt of the CE IVD Mark for its EZ DNA Methylation-Lightning Kit for distribution within the European Union (EU) common market for clinical diagnostic and screening tests of diseases.
The company said the EZ DNA Methylation-Lightning Kit features a ready-to-use conversion reagent, which streamlines the workflow for completion in a little over an hour. The kit is available in spin-column and high-throughput 96-well formats.
According to the company, the chemical treatment of DNA with bisulfite is the prerequisite for many methylation-based diagnostic assays. Clinical diagnostic and screening tests in cancer and developmental diseases are utilizing methylation profiling of DNA to detect the presence of disease and guide treatment.
In addition, the desulphonation and cleanup of converted DNA are performed using unique spin technology, allowing ultra-low elution (10 µl) volumes. The kit achieves the highest conversion efficiencies for the most accurate downstream methylation analysis, said the company.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study